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The cost of healthcare is increasing inexorably in all
countries in the world. Many governments have
focused their activities on promoting the effective and
economic use of resources allocated to healthcare.
Medicines form a small but significant proportion of
total healthcare costs and one that has been increasing
consistently as new medicines appear into the market
place. The writing of a prescription is the most
common therapeutic intervention in medicine and yet
there is much evidence to suggest that this simple task
is not conducted optimally.
Healthcare spending contributes to around 14% of
growth domestic products in the US economy
compared to 7% in the United Kingdom. The UK,
spends around £50 billion on healthcare, mainly in the
public sector, which represents around £900 per
person per year. The amount spent on medicines has
consistently been around 10% with around 550million
prescriptions being dispensed annually.
Each patient receives on average 9.4 items but this
tends to be skewed towards the elderly population.
However the proportion spent on medicines is starting
to rise and is currently 13% of the total. Medicines
expenditure in the UK has increased by an average of
12% per year in the last five years. 81% of the costs
are incurred in primary care and this constitute up to
50% oftheprimary care revenue costs. Within average
general hospitals 3% to 5% of the total revenue
expenditure is spent on medicines. This increase in
expenditure was recently picked up in an independent
report produced by the Audit Commission which
identified potential for savings of £450 million by
promoting good prescribing by general practitioners'.
A House of Commons Select Committee enquiry into
medicines expenditure was recently convened to
examine these increases in costs ofmedicines2.
There are a number of reasons why costs are
increasing. These include:
* Demographic changes in the population. As the
average age in the population becomes older and
as the proportion of elderly patients becomes
greater their pharmaceutical needs increase
* Health screening programmes which have been
particularly targeted attheelderly have uncovered
previously non-identified diseases which
subsequently require treatment.
* Improved diagnostic techniques have again
uncovered more treatable diseases in these
patients.
* New medicines are entering the market place on a
regular basis frequently offering more effective
and less toxic alternatives to existing agents.
Invariably these are more costly
Pharmacoeconomics has been defined as the
measurement of both the costs and consequences of
therapeutic decision making. Pharmacoeconomics
provides a guide for resource allocation but does not
offer a basis on which decisions should be made.
Pharmacoeconomics can help to provide a solution for
dilemmas for decision makers where, for example,
medicines with a worse outcome may be available at a
lower cost and medicines with better outcome and
higher cost can be compared.
Costs and consequences of therapeutic decision
making can be described in a number of ways. Costs
can be direct to the organisation, ie. acquisition costs
of medicines, consumables associated with drug
administration, staff time in preparation and
administration of medicines, laboratory charges for
monitoring for effectiveness and adverse drug
reactions. Indirect costs include lost cost to the
economy and taxation system as well as economic
costs to the patient.
Consequences can be measured in terms of the total
cost associated with a programme where both costs
and consequences are measured in monetary terms
(cost benefit analysis). Cost effectiveness can be
described as an examination of the costs of two or
more programmes which have the same clinical
outcome. Treatments with dissimilar outcomes can
also be analysed by this technique. Cost utility
provides a method for estimating patient preference
and quality oflife measurements within the economic
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setting. The dilemmas facedby decision makers on the
introduction ofa new treatment is indicated in figure1.
FIGURE 1
Decision matrixfor a new treatment
lower cost same cost higher cost
worse reject reject
outcome
same consider optional reject
outcome (CMA)
better dominant adopt
outcome
Outcomes research is now examining the value of
medicines in society by seeking their clinical
effectiveness in terms of efficacy and toxicity but, as
importantly, the humanistic outcomes in terms of
quality of life and health gain which are patient
specific (Figure 2). The third dimension of cost
effectiveness can help society through governments
makepriorities inhealthcare decision making. The use
ofevidence basedmedicine isbecoming a sought after
goal and medicines, by virtue ofthe licensing process
and use of formularies, are one of the only group of
clinical interventions which have been subjected to
health technology assessment.
FIGURE 2
The three dimensions considered in outcomes
research which examine the overall and relative
effectiveness ofaparticular health care intervention.
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The costs associated with adverse drug reactions can
be considerable. eg. The cost for each case of
nephrotoxicity of aminoglycosides was calculated to
be $2500 per case in 19873. Failure to effectively
monitor aminoglycosides levels led to irreversible
vestibular damage in a women who received a
prolonged course of aminoglycosides. Subsequent
legal costs against the hospital were $1.5 million4. The
costs of the bizarre side effects and fatalities of the
anti-arthritic drug benoxaprofen, introduced in the
early 1980's are only now starting to be realised.
The costs of non-compliance with medicines are
significant. In the US ithas been calculated that 11.4%
of all admissions to hospital has been directly
associated with some form ofnoncompliance at acost
of$2150 per patient. Two million hospital admissions
a year result from medication non-compliance at a
total cost of$8.5 billion and it has been estimated that
lost work productivity through non- compliance in the
US is more than $50 billion per year5.
Decision analysis offers a method of pictorial
representing treatment decisions. If the results from
clinical trials are available probabilities can be placed
within the arms ofthe decision tree and outcomes can
be assessed in either monetary or quality units6.
This model can be used for a number of clinical
situations. For example one study examined the
incidence of wound infections which occurred by
giving prophylactic antibiotics too early or too late in
the surgical process and compared with giving them
on induction. A decision tree can be created for the
costs associated with surgery, together with the wound
infection rates published in the original paper. Using
this model it canbe shown that there is an average £51
saving for each operation if the antibiotic is given on
time. Commuted to an average hospital undertaking
10,000 surgical operations a year this reflects a
potential cost saving of half a million pounds. This
approach is referred to as risk management and is a
part ofquality assurance in any givenprocess'.
An example ofthe cost effectiveness ofthe addition of
GMCSF afterautologous bone marrowtransplantation
for lymphoid cancer. A randomised controlled double
blind trial was undertaken in 40 patients to ascertain
the effect of GMCSF with placebo. Outcomes
measured included length of stay, total charges
department, departmental charges, re-hospitalisation
and outpatient charges. In all cases except pharmacy
costs the charges were less with the GMCSF treatment
indicating an overall saving to the organisation at a
better treatment outcome8.
A fundamental element of the use of
pharmacoeconomics in practice is the view point from
which the analysis is conducted. Ideally this should be
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from a societal perspective but frequently it is from a
Government, or Department of Health viewpoint.
Purchasers of healthcare may also have a different
perspective to provider units as might clinicians and
patients may also differ. The pharmaceutical industry
will have another viewpoint which will be focused on
their particular products.
Health economics which is applied to medicines might
compare:
* medicines versus surgery eg H pylori elimination
v HSV
* medicines versus hospitalisation eg avoidance of
admission by using specific antibiotics
* the place ofdiagnostic test costs eg. MRI
* the costs and consequences of prevention
programmes
* the setting in which patients are treated eg.
hospital, outpatient or home - eg home
intravenous antimicrobial therapy
* risk management in avoiding unwanted effects of
medicines
* total quality management where the best
outcomes are sought
A recent study of three groups of health service
decision makers sought to explore the reasons for the
impact, or lack of impact, of the results of economic
evaluations of medicines. An anonymous postal
questionnaire was sentto directors ofpharmacy, health
authority directors of public health and NHS
prescribing advisors. The results
identified the educational need ofthese individuals to
appreciate studies on cost effectiveness and
highlighted that the biggest barrier to implementing
decisions on clinical and economic grounds was the
inability to move funds around within the system9.
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